EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer

Jie Hu, Qilong Liu, Bi Feng, Yanling Lu, Kai Chen

Cancer Research and Treatment · 15.10.2025 · 57 (4) · 1064-1089

DOI: 10.4143/crt.2024.1091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2025. Verfasst von Jie Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology of The Eastern Hospital, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Esophageal Neoplasms, Oxaliplatin, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Esophageal cancer (EC) is a rapidly progressing malignancy characterized by a low survival rate and limited treatment success, largely due to late-stage detection, frequent recurrence, and a high propensity for metastasis, despite ongoing advances in therapeutic strategies. While oxaliplatin (L-OHP) is a potent chemotherapeutic agent that induces apoptosis in EC cells, its effectiveness is significantly hindered by the development of resistance.Materials and Methods The assessment of gene and protein expression was conducted through a combination of quantitative real-time polymerase chain reaction, Western blot, and immunohistochemical staining. Cell viability was assessed using the cell counting kit-8 assay. The interactions among ALYREF, TBL1XR1, KMT2E, and APOC1 were investigated through RNA immunoprecipitation, chromatin immunoprecipitation (ChIP), ChIP-reChIP, RNA pulldown, and dual-luciferase assays. An in vivo mouse model of EC was established.

Results

Expression levels of both APOC1 and ALYREF were elevated in L-OHP–resistant EC tissues and cell lines, and their silencing enhanced sensitivity to L-OHP. TBL1XR1 and KMT2E synergistically upregulated APOC1 expression. Moreover, ALYREF recognized the 5-methylcytosine (m5C) sites on TBL1XR1 and KMT2E mRNAs, stabilizing these transcripts and promoting APOC1 expression. The regulatory role of these interactions was further validated in vivo.

Conclusion

This study demonstrated that ALYREF interacted with the m5C sites on TBL1XR1 and KMT2E mRNAs, enhancing their stability and leading to increased transcription of APOC1, which in turn contributed to L-OHP resistance in EC. These findings suggest that targeting APOC1 could be a promising strategy for overcoming L-OHP resistance in EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmEsophageal NeoplasmsOxaliplatinReceptors, Cytoplasmic and NuclearRepressor ProteinsTranscription FactorsDNA-Binding ProteinsNuclear ProteinsHistone-Lysine N-MethyltransferaseHumansAnimalsMiceGene Expression Regulation, NeoplasticCell Line, TumorXenograft Model Antitumor AssaysUp-RegulationFemaleAntineoplastic AgentsMale

Stichwörter der Autor:innen

ALYREFAPOC1Esophageal neoplasmsH3K4me3 modificationKMT2EOxaliplatin resistanceTBL1XR1

Substanzen

OxaliplatinTBL1XR1 protein, humanReceptors, Cytoplasmic and NuclearRepressor ProteinsTranscription FactorsDNA-Binding ProteinsAntineoplastic AgentsNuclear ProteinsHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Department of Medical Oncology of The Eastern Hospital, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Gastroenterology of The Eastern Hospital, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Zitieren

APA

Hu, J., Liu, Q., Feng, B., Lu, Y., & Chen, K. (2025). ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer. Cancer Research and Treatment, 57(4), 1064-1089. https://doi.org/10.4143/crt.2024.1091

Vancouver

Hu J, Liu Q, Feng B, Lu Y, Chen K. ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer. Cancer Research and Treatment. 2025;57(4):1064-1089. doi:10.4143/crt.2024.1091

BibTeX
@article{Hu2025,
  author = {Hu, Jie and Liu, Qilong and Feng, Bi and Lu, Yanling and Chen, Kai},
  title = {ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer},
  journal = {Cancer Research and Treatment},
  year = {2025},
  volume = {57},
  number = {4},
  pages = {1064--1089},
  doi = {10.4143/crt.2024.1091}
}
Kostenlos starten →